GH Research PLC (NASDAQ:GHRS) Short Interest Update

GH Research PLC (NASDAQ:GHRS) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,280,000 shares, a growth of 11.8% from the December 15th total of 2,040,000 shares. Based on an average daily trading volume, of 72,900 shares, the short-interest ratio is presently 31.3 days. Approximately 7.5% of the company’s stock are sold short.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Canaccord Genuity Group dropped their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Friday, January 10th.

GH Research Stock Up 3.3 %

Shares of GH Research stock traded up $0.28 on Friday, hitting $8.88. The stock had a trading volume of 61,082 shares, compared to its average volume of 78,587. The stock has a market cap of $462.03 million, a price-to-earnings ratio of -11.24 and a beta of 0.84. The business’s 50 day moving average is $8.45 and its two-hundred day moving average is $9.05. GH Research has a twelve month low of $5.50 and a twelve month high of $14.99.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP increased its stake in shares of GH Research PLC (NASDAQ:GHRS) by 19.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,966,726 shares of the company’s stock after buying an additional 656,163 shares during the quarter. GH Research comprises approximately 16.7% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 3rd biggest position. Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).